AVEO Pharmaceuticals (Seite 52)
eröffnet am 11.06.14 13:35:59 von
neuester Beitrag 18.10.22 16:55:22 von
neuester Beitrag 18.10.22 16:55:22 von
Beiträge: 669
ID: 1.195.302
ID: 1.195.302
Aufrufe heute: 0
Gesamt: 74.355
Gesamt: 74.355
Aktive User: 0
ISIN: US0535883070 · WKN: A2P0CL
15,000
USD
+0,07 %
+0,010 USD
Letzter Kurs 20.01.23 NYSE
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 141,00 | +41,00 | |
| 1,0000 | +33,33 | |
| 6,5900 | +31,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 12,150 | -12,72 | |
| 35,69 | -13,71 | |
| 29,40 | -16,95 | |
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 51.347.148 von Eulenfoerster am 21.12.15 16:24:11ist auch Zeit 
394 Mio.$ an Lizenzahlung möglich. Beträchtlich und das nochzu den 311Mio.$ die man am 17.08. verkündet hat. Also Kurse von 2-3$ sind absolut gerechtfertigt. Da geht jetzt die Post ab!
AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in Europe
lebt doch noch .-)
lebt doch noch .-)
Antwort auf Beitrag Nr.: 51.159.762 von sneakee am 24.11.15 08:51:24echt schlimm was momentan Aveo liefert.Die kommen nicht aus den Pushen
sieht irgendwie nach bodenbildung aus.wie festgefahren der kurs.
Trading Spotlight
ja denk ich auch daher stock ich auf :-)
Antwort auf Beitrag Nr.: 51.047.292 von sneakee am 10.11.15 00:03:22
http://www.streetinsider.com/SEC+Filings/Form+8-K+AVEO+PHARM…
Langsam kommt da echt Hoffnung auf, dass AVEO noch was wird
Nochmals Good News
Novartis zahlt nochmals 3.45 Mio. USD an AVEO:http://www.streetinsider.com/SEC+Filings/Form+8-K+AVEO+PHARM…
Langsam kommt da echt Hoffnung auf, dass AVEO noch was wird
Longtime leader of Aveo Oncology steps down from chairman role
Aveo Oncology for most of the 13 years since it was founded, serving as its chairman for the past year, has stepped down from that role, the company said today.
Ha-Ngoc, 63, was CEO of Cambridge-based Aveo (Nasdaq: AVEO) until last year, when Michael Bailey, formerly the chief business officer, took over. Ha-Ngoc was said in a statement by the company today to be stepping down as chairman “to pursue interests outside the company.”
Henri Termeer, longtime CEO of Genzyme who served as Aveo’s chairman until last year, will resume that role. In a statement, Termeer said that “Tuan has played a fundamental role in building Aveo’s business over his long tenure at the company. We thank him profoundly for his leadership of the company and wish him the best in his future endeavors.”
Featured Jobs
Director / Sr. Director, Business Development
Moderna Therapeutics
Head, Investor Relations
Moderna Therapeutics
Marketing Manager
Greg Nanigian and Associates, Inc.
Post a Job
See More Jobs
The company has had a tough road in recent years, to say the least. The company was thought by many to be headed for approval of its potential kidney cancer drug, tivozanib, in early 2013. But an FDA panel voted against full approval in May of that year, because trial data indicated that the drug did not prove the drug helped patients with the disease to live longer.
As head of the company, Ha-Ngoc was widely criticized for what was seen as a faulty trial design. But he maintained that its drug improved so-called progression-free survival (the length of time after taking a new drug before a cancer starts growing again) about three months longer than Nexavar, the existing standard of care. The only reason patients given tivozanib appeared to die slightly sooner than those who first received Nexavar was that the company allowed patients whose cancer had progressed after that treatment to switch over to tivozanib. Although Ha-Ngoc said that decision was made “for humanitarian reasons,” such patients got the benefits of two drugs, rather than one.
Many in the investment community seemed to blame Ha-Ngoc nonetheless for not stepping down earlier. News of his departure today spurred a 10 percent increase in share price as of $11 a.m.
http://www.bizjournals.com/boston/blog/bioflash/2015/11/long…
Aveo Oncology for most of the 13 years since it was founded, serving as its chairman for the past year, has stepped down from that role, the company said today.
Ha-Ngoc, 63, was CEO of Cambridge-based Aveo (Nasdaq: AVEO) until last year, when Michael Bailey, formerly the chief business officer, took over. Ha-Ngoc was said in a statement by the company today to be stepping down as chairman “to pursue interests outside the company.”
Henri Termeer, longtime CEO of Genzyme who served as Aveo’s chairman until last year, will resume that role. In a statement, Termeer said that “Tuan has played a fundamental role in building Aveo’s business over his long tenure at the company. We thank him profoundly for his leadership of the company and wish him the best in his future endeavors.”
Featured Jobs
Director / Sr. Director, Business Development
Moderna Therapeutics
Head, Investor Relations
Moderna Therapeutics
Marketing Manager
Greg Nanigian and Associates, Inc.
Post a Job
See More Jobs
The company has had a tough road in recent years, to say the least. The company was thought by many to be headed for approval of its potential kidney cancer drug, tivozanib, in early 2013. But an FDA panel voted against full approval in May of that year, because trial data indicated that the drug did not prove the drug helped patients with the disease to live longer.
As head of the company, Ha-Ngoc was widely criticized for what was seen as a faulty trial design. But he maintained that its drug improved so-called progression-free survival (the length of time after taking a new drug before a cancer starts growing again) about three months longer than Nexavar, the existing standard of care. The only reason patients given tivozanib appeared to die slightly sooner than those who first received Nexavar was that the company allowed patients whose cancer had progressed after that treatment to switch over to tivozanib. Although Ha-Ngoc said that decision was made “for humanitarian reasons,” such patients got the benefits of two drugs, rather than one.
Many in the investment community seemed to blame Ha-Ngoc nonetheless for not stepping down earlier. News of his departure today spurred a 10 percent increase in share price as of $11 a.m.
http://www.bizjournals.com/boston/blog/bioflash/2015/11/long…
die derzeitige Market Cap: 75.16M ist ein witz...da ist genug luft nach oben.
Antwort auf Beitrag Nr.: 51.041.820 von Moneyplus am 09.11.15 14:34:28
Die Cash-Reserven beinhalten ja auch keine weiteren Meilenzahlungen die ja noch fließen können.
Das ertse Quartal 2016 wird spannend. Hier steckt eine Menge Potenzial noch.
Zitat von Moneyplus: Also bei aktuell 37 Mio. USD Cash (siehe Q3-Zahlen) sollte "Geld ausgehen" wohl kein Problem darstellen
Die Cash-Reserven beinhalten ja auch keine weiteren Meilenzahlungen die ja noch fließen können.
Das ertse Quartal 2016 wird spannend. Hier steckt eine Menge Potenzial noch.
Durchsuchen
